Q2. What are the future works mentioned in the paper "Diagnostic utility of idh1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone" ?
If effective IDH1/2 mutation inhibitors become available in the future, PCR mutation analysis on cases of dedifferentiated chondrosarcoma help guide treatment decisions.
Q3. What is the role of IDH in the Krebs cycle?
IDH is an important homodimeric enzyme in the citric acid cycle (the Krebs cycle) and normally catalyzes the decarboxylation of isocitrate (ICT) to α–ketoglutarate (α-KG).
Q4. What is the recent study of IDH1 inhibitors?
Recent in vitro study revealed that high doses of IDH1 inhibitor AGI-5198 inhibited colony formation and migration, interrupted cell cycling, and induced apoptosis using chondrosarcoma cell lines, which revealed anti-tumor activity of the IDH1 inhibitor (17).
Q5. What is the common primary malignancy of bone after osteosarcoma?
a malignant cartilaginous tumor, is the second most common primary malignancy of bone after osteosarcoma, often arising from the pelvis, femur, or humerus.
Q6. What is the main drawback of performing mutational analysis on bone tumors?
One potential drawback of performing mutational analysis on bone tumors is that the decalcification procedure involves hydrochloric acid which is known to cause DNA damage through chemical hydrolysis which has been previously discussed by Kerr and colleagues in their analysis of IDH1/2 mutations in chondoblastic osteosarcoma (15) Consequently, tumor sections with significant bone matrix may be subjected to this process, often rendering them unsuitable for these studies.
Q7. What is the idh1 mutation in cartilaginous tumors?
Although the IDH1 R132H mutation occurs in approximately 70% of WHO grade II and III gliomas (7), it was detected in only 17% of the IDH 1/2 mutations present in cartilaginous tumors in one study (14) and 0% (0/14 positive cases) in another study (15).
Q8. How many cases of chondrosarcoma were collected?
A total of 68 cases were collected for IDH1/2 mutation analysis and included 31 conventional chondrosarcomas, 23 dedifferentiated chondrosarcomas, and 14 UPS of bone.
Q9. What is the way to determine IDH1/2 mutation status?
While the IDH1 R132H monoclonal antibody appears to be a reliable surrogate for mutation status, the low rate of its prevalence in dedifferentiated chondrosarcoma limits its usefulness in this setting.
Q10. What is the definition of a dedifferentiated chondrosarcoma?
Dedifferentiated chondrosarcoma is a highly aggressive biphasic mesenchymal tumor consisting of a well-differentiated cartilaginous component admixed with area of high-grade sarcoma.
Q11. What was the CT value of the mutated IDH1/2 gene?
Samples were classified as mutation-positive (IDH1 Mut R132, IDH2 Mut R172, and IDH1 Mut R100) if the ΔCT value was less than or equal to the ΔCT cutoff value of the respective mutation detection assay.